CD19 and diffuse large B-cell lymphoma: DoR, PFS, and OS appear to be improved in patients who receive tafasitamab + LEN as second-line therapy for R/R DLBCL, compared with more heavily pre-treated patients,14 however there are as yet no studies to assess relative effectiveness of different anti-CD19 treatment sequences.